RxDoctor Payments Data

Kimberly Ryan, APRN

Adult Health · Wethersfield, CTNPI 1124323472

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (54.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 78.3% of it on its own, with 51 other manufacturers making up the rest. Among adult health clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$73,565in general payments, 2019–2025

Across 849 payments — averaging $86.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$58K
  • Johnson & Johnson$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Novartis$1K
  • Rigel Pharmaceuticals, Inc.$804
  • Bayer$795
  • plus $11K from 46 others

What the payments were for

  • Speaking & faculty fees$39,95054%
  • Travel & lodging$13,81919%
  • Food & beverage$18,46825%
  • Education$1,3282%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$73,565 in reported general payments places this provider in the 95th percentile of 418 adult health providers in Connecticut.

See all adult health providers in Connecticut

Medicare billing

Part B allowed, 2024
$316,253
Medicare patients
250
Services billed
9,524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide22$313,715
RevlimidLenalidomide15$250,838
BrukinsaZanubrutinib12$187,005
ZytigaAbiraterone Acetate11$144,296
XareltoRivaroxaban15$21,491
EliquisApixaban16$10,161
Enoxaparin Sodium11$3,814
Hydroxyurea33$904
Letrozole39$721
Ondansetron Hcl45$641
Acyclovir42$539
Dexamethasone28$537
Anastrozole25$342
Warfarin Sodium24$281
Gabapentin35$244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$483$250,83815 claims
Beigene USA, Inc.Brukinsa$400$187,00512 claims
Johnson & JohnsonZytiga, Xarelto$1,456$165,78726 claims
PfizerEliquis$757$10,16116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 418 adult health providers in Connecticut.

Other adult health in Wethersfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →